Literature DB >> 4075292

Protection from cis-dichlorodiammineplatinum-induced cell inactivation by aldehydes involves cell membrane amino groups.

J M Dornish, E O Pettersen.   

Abstract

The effect of cis-dichlorodiammineplatinum (cis-DDP) alone or in combination with the vitamin B6 analogs pyridoxal, pyridoxal 5'-phosphate and pyridoxine was tested on human NHIK 3025 cells. Cell inactivation was measured as loss of colony-forming ability following 2 h drug treatment. The cell inactivating effect of cis-DDP was significantly reduced when the aldehyde analogs pyridoxal or pyridoxal 5'-phosphate were simultaneously present with cis-DDP. The alcohol analog pyridoxine, however, did not affect cis-DDP-induced cell inactivation to any degree. Pyridoxine, pyridoxal or pyridoxal 5'-phosphate treatment alone had no effect on cell survival. Both pyridoxal and pyridoxal 5'-phosphate form Schiff bases with protein amino groups, but pyridoxal 5'-phosphate is cell membrane-impermeable. Therefore protection from cis-DDP-induced cell inactivation by aldehydes appears to involve cell membrane amino groups.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 4075292     DOI: 10.1016/0304-3835(85)90133-8

Source DB:  PubMed          Journal:  Cancer Lett        ISSN: 0304-3835            Impact factor:   8.679


  4 in total

Review 1.  Molecular mechanisms of resistance and toxicity associated with platinating agents.

Authors:  Cara A Rabik; M Eileen Dolan
Journal:  Cancer Treat Rev       Date:  2006-11-03       Impact factor: 12.111

Review 2.  Cellular accumulation of the anticancer agent cisplatin: a review.

Authors:  D P Gately; S B Howell
Journal:  Br J Cancer       Date:  1993-06       Impact factor: 7.640

3.  Synergistic interaction between cisplatin and taxol in human ovarian carcinoma cells in vitro.

Authors:  A P Jekunen; R D Christen; D R Shalinsky; S B Howell
Journal:  Br J Cancer       Date:  1994-02       Impact factor: 7.640

4.  Synergistic cell inactivation by cis-dichlorodiammineplatinum in combination with 1-propargyl-5-chloropyrimidin-2-one.

Authors:  J M Dornish; E O Pettersen; R Oftebro
Journal:  Br J Cancer       Date:  1987-09       Impact factor: 7.640

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.